Evidence map›Paper›PMID 33587330›Full record

ArticlePhytotherapy research : PTR2021

Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.

Katherine D Lynch, Michelle L Montonye, Dan-Dan Tian, Tarana Arman, Victoria O Oyanna, Baron J Bechtold, Tyler N Graf, Nicholas H Oberlies, Mary F Paine, John D Clarke

Open access · greenAbstract read
In one paragraph

Article in Phytotherapy research : PTR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Katherine D LynchDepartment of Pharmaceutical Sciences, Washington State University-Spokane, Spokane, Washington, USA.ORCID https://orcid.org/0000-0003-0509-7852
Michelle L MontonyeDepartment of Pharmaceutical Sciences, Washington State University-Spokane, Spokane, Washington, USA.
Dan-Dan TianDepartment of Pharmaceutical Sciences, Washington State University-Spokane, Spokane, Washington, USA.
Tarana ArmanDepartment of Pharmaceutical Sciences, Washington State University-Spokane, Spokane, Washington, USA.
Victoria O OyannaDepartment of Pharmaceutical Sciences, Washington State University-Spokane, Spokane, Washington, USA.
Baron J BechtoldDepartment of Pharmaceutical Sciences, Washington State University-Spokane, Spokane, Washington, USA.
Tyler N GrafDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina, USA.
Nicholas H OberliesDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina, USA.
Mary F PaineDepartment of Pharmaceutical Sciences, Washington State University-Spokane, Spokane, Washington, USA.
John D ClarkeDepartment of Pharmaceutical Sciences, Washington State University-Spokane, Spokane, Washington, USA.ORCID https://orcid.org/0000-0003-3835-7761
Washington State University Spokane · USUniversity of North Carolina at Greensboro · US

Funding

Pharmacology CoreU54AT008909 · NCCIH · WASHINGTON STATE UNIVERSITY · PI PAINE, MARY F · 2015 to 2024
$22.4M
Microcystin-LR toxicity in nonalcoholic steatohepatitisR00ES024455 · NIEHS · WASHINGTON STATE UNIVERSITY · PI CLARKE, JOHN DANIEL · 2017 to 2019
$715k
Enteric and hepatic transporter mechanisms for pharmacokinetic natural product-drug interactionsR21AT011101 · NCCIH · WASHINGTON STATE UNIVERSITY · PI CLARKE, JOHN DANIEL · 2020 to 2021
$421k
Risk of xenobiotic-drug interactions in chronic diseaseR56AT010650 · NCCIH · WASHINGTON STATE UNIVERSITY · PI CLARKE, JOHN DANIEL · 2020 to 2020
$223k
NCCIH NIH HHS AT008909NCCIH NIH HHS R21 AT011101NCCIH NIH HHS R56 AT010650NCCIH NIH HHS U54 AT008909NIEHS NIH HHS R00 ES024455NIH HHSWashington State University College of Pharmacy and Pharmaceutical Sciences
6 · The paper itself

Abstract

Silybum marianum (L.) Gaertn. (Asteraceae), commonly known as milk thistle, is a botanical natural product used to self-treat multiple diseases such as Type 2 diabetes mellitus and nonalcoholic steatohepatitis (NASH). An extract from milk thistle seeds (achenes), termed silymarin, is comprised primarily of several flavonolignans. Systemic concentrations of these flavonolignans can influence the potential biologic effects of silymarin and the risk for pharmacokinetic silymarin-drug interactions. The aims of this research were to determine the roles of organic anion transporting polypeptides (OATPs/Oatps) in silymarin flavonolignan disposition and in pharmacokinetic silymarin-drug interactions. The seven major flavonolignans from silymarin were determined to be substrates for OATP1B1, OATP1B3, and OATP2B1. Sprague Dawley rats were fed either a control diet or a NASH-inducing diet and administered pitavastatin (OATP/Oatp probe substrate), followed by silymarin via oral gavage. Decreased protein expression of Oatp1b2 and Oatp1a4 in NASH animals increased flavonolignan area under the plasma concentration-time curve (AUC) and maximum plasma concentration. The combination of silymarin inhibition of Oatps and NASH-associated decrease in Oatp expression caused an additive increase in plasma pitavastatin AUC in the animals. These data indicate that OATPs/Oatps contribute to flavonolignan cellular uptake and mediate the interaction between silymarin and NASH on pitavastatin systemic exposure.

Indexed as

AnimalsAntioxidantsDrug InteractionsFlavonoidsFlavonolignansHumansMaleNon-alcoholic Fatty Liver DiseaseOrganic Anion TransportersQuinolinesRatsRats, Sprague-DawleySilybum marianumSilymarinAntioxidantsFlavonoidsFlavonolignansOrganic Anion TransporterspitavastatinQuinolinesSilymarinflavonolignansnonalcoholic steatohepatitisorganic anion transporting polypeptidepharmacokineticspitavastatinsilymarin

Identifiers

PMID33587330
PMCPMC8217340
OpenAlexW3129402490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.